>Mercado europeo de tratamiento con terapia de células CAR-T, por producto (células CAR-T autólogas, células CAR-T alogénicas), estructura (células CAR-T de primera generación, células CAR-T de segunda generación, células CAR-T de tercera generación, células CAR-T de cuarta generación), antígenos específicos (antígenos en tumores sólidos, antígenos en neoplasias hematológicas, otros), marca (Yescarta, Kymriah, Tecartus, otros), aplicación terapéutica (neoplasias hematológicas, cáncer de páncreas, cáncer de mama, cáncer de pulmón, cáncer gástrico, mieloma múltiple, leucemia linfocítica crónica, linfoma de células del manto, linfoma folicular, linfoma difuso de células B grandes, leucemia linfoblástica aguda, otros), usuario final (hospitales, clínicas especializadas, otros), canal de distribución (farmacias de hospitales, otros), país (Alemania, Reino Unido, Francia, Italia, España, Países Bajos, Rusia, Suiza, Turquía, Austria, Noruega, Hungría, Lituania, Irlanda, Polonia, Resto de Europa) Tendencias de la industria y pronóstico hasta 2028
Análisis y perspectivas del mercado : mercado europeo de tratamiento con terapia con células CAR-T
Se espera que el mercado de tratamiento de terapia con células CAR-T gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 29,4% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 10.594,65 millones para 2028. Aumento en el uso de la terapia con células CAR-T para el tratamiento del cáncer y enfermedades infecciosas que actúa como impulsor del crecimiento del mercado de tratamiento de terapia con células CAR-T.
La terapia con células CAR-T o células T con receptores de antígenos quiméricos son aquellas células T que se modifican genéticamente para producir un receptor de células T artificial que se puede utilizar como inmunoterapia para el tratamiento de diversos tipos de cáncer. Los receptores de antígenos quiméricos son aquellas proteínas receptoras que se han modificado en los laboratorios para proporcionar a las células T la novedosa capacidad de dirigirse a una proteína específica.
El aumento de la conciencia sobre las inmunoterapias llevó a las personas a encontrarse con varios tipos de terapias CAR-T y su eficacia y, por lo tanto, actúa como impulsor del mercado de tratamiento de terapia con células CAR-T. Los efectos secundarios adversos de las terapias restringen a alguna población a optar por dicho tratamiento, lo que afecta el valor del producto y, por lo tanto, actúa como una restricción para el crecimiento del mercado de tratamiento de terapia con células CAR-T. La presencia de productos en desarrollo sugiere que los actores del mercado están constantemente involucrados en la fabricación de medicamentos innovadores, lo que actúa como una oportunidad para el mercado de tratamiento de terapia con células CAR-T. El largo tiempo de aprobación de las inmunoterapias restringe al fabricante del producto para obtener un beneficio potencial en el mercado e impacta el tamaño general del mercado, por lo tanto, actúa como un desafío para el crecimiento del mercado de tratamiento de terapia con células CAR-T.
El informe de mercado de tratamiento con terapia de células CAR-T proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, comuníquese con nosotros para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de tratamiento con terapia de células CAR-T en Europa
El mercado de tratamiento con terapia de células CAR-T está segmentado en función del producto, la estructura, los antígenos objetivo, la marca, la aplicación terapéutica, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.
- En función del producto, el mercado de tratamiento con terapia con células CAR-T se segmenta en células CAR-T autólogas y células CAR-T alogénicas. En 2021, se espera que el segmento de células CAR-T autólogas domine el mercado de tratamiento con terapia con células CAR-T porque los medicamentos aprobados para la terapia con células CAR-T son de naturaleza autóloga.
- Sobre la base de la estructura, el mercado de tratamiento con terapia de células CAR-T se segmenta en células CAR-T de primera generación, células CAR-T de segunda generación, células CAR-T de tercera generación y células CAR-T de cuarta generación. En 2021, se espera que el segmento de células CAR-T de segunda generación domine el mercado de tratamiento con terapia de células CAR-T porque las terapias aprobadas tienen una estructura basada en la segunda generación.
- Sobre la base de los antígenos específicos, el mercado de tratamiento con terapia de células CAR-T se segmenta en antígenos en tumores sólidos, antígenos en neoplasias hematológicas y otros. En 2021, se espera que el segmento de antígenos en neoplasias hematológicas domine el mercado de tratamiento con terapia de células CAR-T porque los medicamentos aprobados para la terapia de células CAR-T se utilizan principalmente para neoplasias hematológicas y se está llevando a cabo un amplio desarrollo de investigación.
- En función de la marca, el mercado de tratamiento con terapia de células CAR-T se segmenta en yescarta, kymriah, tecartus y otros. En 2021, se espera que el segmento yescarta domine el mercado de tratamiento con terapia de células CAR-T porque yescarta es la primera terapia con células CAR-T aprobada para la clase terapéutica oncológica.
- On the basis of therapeutic application, the CAR-T cell therapy treatment market is segmented into hematological malignancies, pancreatic cancer, breast cancer, lung cancer, gastric cancer, multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia and others. In 2021, hematological malignancies segment is expected to dominate the CAR-T cell therapy treatment market because yescarta accounts the major revenue in the market and the follicular lymphoma is the major indication for yescarta.
- On the basis of end user, the CAR-T cell therapy treatment market is segmented into hospitals, specialty clinics and others. In 2021, hospitals segment is dominating the CAR-T cell therapy treatment market because CAR-T cell therapy required highly trained professionals with advanced technology laboratories.
- On the basis of distribution channel, the CAR-T cell therapy treatment market is segmented into hospitals pharmacy and others. In 2021, hospitals pharmacy segment is expected to dominate the CAR-T cell therapy treatment distribution channel because hospitals pharmacy are the central part of the hospitals, all the infusion related and medication related delivery sold by the pharmacy department.
CAR-T Cell Therapy Treatment Market Country Level Analysis
The CAR-T cell therapy treatment market is analyzed and market size information is provided on based on the country, product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel as referenced above.
The countries covered in the Europe CAR-T cell therapy treatment market report are the Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, and Rest of Europe.
The autologous CAR-T cells segment in Germany is dominating the Europe CAR-T cell therapy treatment market owing to prevalence of cancer.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rise in Awareness about Immunotherapies is boosting the CAR-T Cell Therapy Treatment Market Growth
El mercado de tratamiento con terapia de células CAR-T también le proporciona un análisis detallado del mercado para cada país, el crecimiento de la industria del tratamiento con terapia de células CAR-T con las ventas de tratamiento con terapia de células CAR-T, el impacto del avance en la tecnología de tratamiento con terapia de células CAR-T y los cambios en los escenarios regulatorios con su apoyo al mercado de tratamiento con terapia de células CAR-T. Los datos están disponibles para el período histórico de 2011 a 2019.
Análisis del panorama competitivo y de la cuota de mercado de los tratamientos con terapia con células CAR-T
El panorama competitivo del mercado de tratamiento con terapia de células CAR-T proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las líneas de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y amplitud de los productos, el dominio de las aplicaciones y la curva de la línea de vida de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa relacionado con el mercado de tratamiento con terapia de células CAR-T.
Las principales empresas que participan en el informe de mercado de tratamiento con terapia de células CAR-T son Autolus, Amgen Inc., bluebird bio, Inc., Adaptimmune Therapeutics plc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc, AbbVie Inc., Novartis AG, Kite Pharma (una subsidiaria de Gilead Sciences, Inc.), Cellectis, TC BIOPHARM, Celyad Oncology, entre otros actores nacionales y globales. Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.
Numerosas empresas de todo el mundo también lanzan productos y firman acuerdos que aceleran el mercado de tratamiento con terapia celular CAR-T.
Por ejemplo,
- En diciembre de 2020, Atara Biotherapeutics, Inc. inició una colaboración con Bayer AG para el desarrollo de terapias con células T CAR dirigidas a la mesotelina para tumores sólidos. Según el acuerdo, la empresa está muy centrada en el desarrollo de ATA2271 para tratar el mesotelioma pleural maligno y el cáncer de pulmón de células no pequeñas. Esta colaboración aceleró la investigación y el desarrollo de ATA2271 por parte de la empresa y le permitió convertirse en el principal fabricante de terapias con células T CAR alogénicas.
La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando el mercado de la empresa en el mercado de tratamiento de terapia con células CAR-T, lo que también brinda el beneficio para que la organización mejore su oferta de tratamiento de terapia con células CAR-T.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
- introduction
- OBJECTIVES OF THE STUDY
- MARKET DEFINITION
- OVERVIEW of EUROPE CAR-T cell therapy treatment MARKET
- LIMITATIONs
- MARKETS COVERED
- MARKET SEGMENTATION
- MARKETS COVERED
- geographical scope
- years considered for the study
- currency and pricing
- DBMR TRIPOD DATA VALIDATION MODEL
- MULTIVARIATE MODELLING
- PRODUCT LIFELINE CURVE
- primary interviews with key opinion leaders
- DBMR MARKET POSITION GRID
- vendor share analysis
- MARKET product COVERAGE GRID
- secondary sourcEs
- assumptions
- EXECUTIVE SUMMARY
- premium insight
- Epidemiology
- Pipeline analysis
- Market Overview
- Drivers
- increase in usage of CAR-T CELL THERAPY for the treatment of cancer and infectious diseases
- increasing prevalEnce of cancer
- rise in awareness about immunotherapies
- increasing investment in research and development
- adoption of CAR-T cell therapy treatment in Emerging markets
- restraints
- adverse side effects of therapies
- high cost associated with therapies
- logistic challenge associated with CAR-T therapies
- availability of alternatives for tumor treatment
- opportunities
- presence of pipeline producTs
- strategiC initiatives by market players
- Rise in expenditure in healthcare sector
- challenges
- long approval time for immunotherapies
- lack of skilled professionals
- IMPACT OF COVID-19 ON EUROPE CAR-T CELL THERAPY TREATMENT MARKET
- IMPACT ON PRICE
- IMPACT ON DEMAND
- IMPACT ON SUPPLY CHAIN
- STRATEGIC DECISION FOR MANUFACTURERS
- CONCLUSION
- Europe CAR-T Cell Therapy Treatment MARKET, BY PRODUCT
- overview
- Autologous CAR-T Cells
- Allogeneic CAR-T Cells
- Europe CAR-T CELL THERAPY TREATMENT MARKET, BY Structure
- overview
- First Generation CAR-T Cells
- Second Generation CAR-T Cells
- Third Generation CAR-T Cells
- Fourth Generation CAR-T Cells
- Europe CAR-T CELL THERAPY TREATMENTMARKET, BY Targeted Antigens
- overview
- Antigens on Hematologic Malignancies
- Cluster of Differentiation-19 (CD-19)
- Cluster of Differentiation-30 (CD-30)
- Cluster of Differentiation-22 (CD-22)
- Cluster of Differentiation-20 (CD-20)
- Cluster of Differentiation-33 (CD-33)
- Antigens on Solid Tumors
- Human Epidermal Growth Factor Receptor-2 (HER-2)
- Epidermal Growth Factor Receptors Variant III (EGFRV-III)
- Mesothelin (MSLN)
- Prostate-Specific Membrane Antigen (PSMA)
- Interleukin-13RA2 (IL13RA2)
- Disialoganglioside 2 (GD2)
- Glypican-3 (GPC3)
- Others
- OTHERS
- Europe CAR-T cell therapy treatment MARKET, BY brand
- overview
- yescarta
- KYMRIAH
- TECARTUS
- others
- Europe CAR-T cell therapy treatment MARKET, BY therapeutic application
- overview
- Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma
- Acute Lymphoblastic Leukaemia (ALL)
- Mantle Cell Lymphoma
- Multiple Myeloma
- Hematologic Malignancies
- Leukemia
- Lymphoma
- Myeloma
- Others
- Lung Cancer
- Chronic Lymphocytic Leukemia
- Gastric Cancer
- Pancreatic Cancer
- Breast Cancer
- others
- Europe CAR-T cell therapy treatment MARKET, BY end user
- overview
- hospitals
- Specialty Clinics
- others
- Europe CAR-T cell therapy treatment MARKET, BY distribution channel
- overview
- hospital Pharmacy
- others
- Europe CAR-T cell therapy treatment market by geography
- EUROPE
- germany
- u.k
- France
- Italy
- Spain
- NETHERLANDS
- Russia
- Switzerland
- Belgium
- Turkey
- Austria
- Norway
- Hungary
- Lithuania
- Ireland
- Poland
- Rest of Europe
- Europe CAR-T Cell Therapy Treatment Market: COMPANY landscape
- company share analysis: europe
- swot analysis
- company profile
- kite pharma (A subsidiary of GILEAD SCIENCES, INC.)
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Novartis AG
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Abbvie inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Adaptimmune Therapeutics plc
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Amgen Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Atara Biotherapeutics, Inc.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- aurora biopharmA
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Autolus
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Bellicum Phamaceuticals, Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- BioAtla Inc.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- bluebird bio, inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Bristol-Myers Squibb Company
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- carina biotech
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- cartherics pty ltd
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- cartesian therapeutics, inc.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- cellectis SA
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- celyad oncology SA
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Johnson & Johnson Services, Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- sorrento therapeutics, INC.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- tc biopharm Limited
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- tessa therapeutics ltd.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- tmunity therapeutics
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- mustang bio
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Xyphos (A Subsidiary of Astellas Pharma Inc.)
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- ziopharm oncology, inc.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- questionnaire
- related reports
Lista de Tablas
TABLE 1 Europe CAR-T cell therapy treatment Market, pipeline analysis
TABLE 2 Below provided are the alternative chemotherapies of CAR-T cell therapy:
TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)
TABLE 4 Europe CAR-T CELL THERAPY TREATMENTMarket, By MOLECULE, 2019-2028 (USD Million)
TABLE 5 Europe Autologous CAR-T Cells in CAR-T CELL THERAPY TREATMENTMarket, By Region, 2017-2028 (USD Million)
TABLE 6 Europe Allogeneic CAR-T Cells in CAR-T CELL THERAPY TREATMENTMARKET, By Region, 2019-2028 (USD Million)
TABLE 7 Europe CAR-T CELL THERAPY TREATMENTMarket, By Structure, 2019-2028 (USD Million)
Celyad is engaged in the manufacturing of CYAD-211, a first generation CAR-T cell therapy expressing BCMA targeting chimeric antigen receptor which interferes with the expression of the CD3ζ of T cell receptor complex.
TABLE 8 Europe First Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 9 Europe Second Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 10 Europe Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 11 Europe Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 12 Europe CAR-T CELL THERAPY TREATMENTMarket, By targeted antigens, 2019-2028 (USD Million)
TABLE 13 Europe Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 14 Europe Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Hematologic Malignancies, 2019-2028 (USD Million)
TABLE 15 Europe Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)
TABLE 16 Europe Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Solid Tumors, 2019-2028 (USD Million)
TABLE 17 Europe others in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)
TABLE 18 Europe YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 19 Europe YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 20 Europe KYMRIAH in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 21 Europe TECARTUS in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 22 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 23 Europe CAR-T cell therapy treatment Market, By therapeutic type, 2019-2028 (USD Million)
TABLE 24 Europe Follicular Lymphoma in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)
TABLE 25 Europe Diffuse Large B-Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 26 Europe ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 27 Europe Mantle Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 28 Europe Multiple Myeloma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 29 Europe hematologic malignancies in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 30 Europe hematologic malignancies on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By therapeutic application, 2019-2028 (USD Million)
TABLE 31 Europe Lung Cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 32 Europe chronic lymphocytic leukemia in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 33 Europe gastric cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 34 Europe pancreatic cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 35 Europe breast cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 36 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 37 Europe CAR-T cell therapy treatment Market, By END USER, 2019-2028 (USD Million)
TABLE 38 Europe hospitals in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)
TABLE 39 Europe specialty clinics in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 40 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 41 Europe CAR-T cell therapy treatment Market, By distribution channel, 2019-2028 (USD Million)
TABLE 42 Europe hospital pharmacy in CAR-T cell therapy treatment Market, By distribution channel, 2017-2028 (USD Million)
TABLE 43 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 44 Europe CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)
TABLE 45 Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 46 Europe CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 47 Europe CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 48 europe Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 49 Europe Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 50 Europe CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 51 Europe CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 52 Europe Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 53 Europe CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 54 Europe CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 55 Germany CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 56 Germany CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 57 Germany CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 58 Germany Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 59 Germany Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 60 Germany CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 61 Germany CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 62 Germany Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 63 Germany CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 64 Germany CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 65 U.K CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 66 U.K CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 67 U.K CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 68 U.K Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 69 U.K Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 70 U.K CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 71 U.K CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 72 U.K Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 73 U.K CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 74 U.K CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 75 FRANCE CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 76 FRANCE CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 77 FRANCE CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 78 FRANCE Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 79 FRANCE Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 80 FRANCE CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 81 FRANCE CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 82 FRANCE Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 83 FRANCE CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 84 FRANCE CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 85 ITALY CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 86 ITALY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 87 ITALY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 88 ITALY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 89 ITALY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 90 ITALY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 91 ITALY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 92 ITALY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 93 ITALY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 94 ITALY CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 95 Spain CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 96 SPAIN CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 97 SPAIN CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 98 SPAIN Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 99 SPAIN Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 100 SPAIN CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 101 SPAIN CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 102 SPAIN Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 103 SPAIN CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 104 SPAIN CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 105 netherlands CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 106 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 107 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 108 NETHERLANDS Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 109 NETHERLANDS Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 110 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 111 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 112 NETHERLANDS Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 113 NETHERLANDS CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 114 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 115 Russia CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 116 RUSSIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 117 RUSSIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 118 RUSSIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 119 RUSSIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 120 RUSSIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 121 RUSSIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 122 RUSSIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 123 RUSSIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 124 RUSSIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 125 Switzerland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 126 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 127 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 128 SWITZERLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 129 SWITZERLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 130 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 131 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 132 SWITZERLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 133 SWITZERLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 134 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 135 belgium CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 136 BELGIUM CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 137 BELGIUM CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 138 BELGIUM Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 139 BELGIUM Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 140 BELGIUM CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 141 BELGIUM CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 142 BELGIUM Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 143 BELGIUM CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 144 BELGIUM CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 145 turkey CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 146 TURKEY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 147 TURKEY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 148 TURKEY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 149 TURKEY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 150 TURKEY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 151 TURKEY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 152 TURKEY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 153 TURKEY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 154 turkey CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 155 Austria CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 156 AUSTRIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 157 AUSTRIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 158 AUSTRIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 159 AUSTRIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 160 AUSTRIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 161 AUSTRIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 162 AUSTRIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 163 AUSTRIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 164 Austria CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 165 norway CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 166 NORWAY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 167 NORWAY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 168 NORWAY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 169 NORWAY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 170 NORWAY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 171 NORWAY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 172 NORWAY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 173 NORWAY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 174 Norway CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 175 Hungary CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 176 HUNGARY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 177 HUNGARY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 178 HUNGARY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 179 HUNGARY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 180 HUNGARY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 181 HUNGARY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 182 HUNGARY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 183 HUNGARY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 184 Hungary CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 185 Lithuania CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 186 LITHUANIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 187 LITHUANIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 188 LITHUANIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 189 LITHUANIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 190 LITHUANIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 191 LITHUANIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 192 LITHUANIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 193 LITHUANIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 194 Lithuania CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 195 Ireland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 196 IRELAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 197 IRELAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 198 IRELAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 199 IRELAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 200 IRELAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 201 IRELAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 202 IRELAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 203 IRELAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 204 ireland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 205 Poland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 206 POLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 207 POLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 208 POLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 209 POLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 210 POLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 211 POLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 212 POLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 213 POLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 214 Poland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 215 Rest of Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
Lista de figuras
FIGURE 1 Europe CAR-T cell therapy treatment MARKET: SEGMENTATION
FIGURE 2 EUROPE CAR-T cell therapy treatment MARKET: DATA TRIANGULATION
FIGURE 3 Europe CAR-T cell therapy treatment Market: DROC ANALYSIS
FIGURE 4 Europe CAR-T cell therapy treatment market: Europe VS REGIONAL MARKET ANALYSIS
FIGURE 5 Europe CAR-T cell therapy treatment Market: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE CAR-T cell therapy treatment MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE CAR-T cell therapy treatment MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE CAR-T cell therapy treatment MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE CAR-T cell therapy treatment MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE car-t cell therapy treatment MARKET: MARKET product COVERAGE GRID
FIGURE 11 Europe car-t cell therapy treatment market: SEGMENTATION
FIGURE 12 increasing investment in research and development is expected to drive THE Europe CAR-T cell therapy treatment market IN THE FORECAST PERIOD OF 2021 to 2028
FIGURE 13 Autologus car-t cells SEGMENT is expected to account for the largest share of the Europe CAR-T CELL THERAPY TREATMENT market in 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGEs OF Europe CAR-T cell therapy treatment Market
FIGURE 15 New Cancer Cases Worldwide, (2018)
FIGURE 16 Europe Cancer Incidence (2018)
FIGURE 17 Cancer Death By Type (in million), world, 2017
FIGURE 18 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2021
FIGURE 19 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2019-2028 (USD Million)
FIGURE 20 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, CAGR (2021-2028)
FIGURE 21 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, LIFELINE CURVE
FIGURE 22 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2021
FIGURE 23 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2019-2028 (USD Million)
FIGURE 24 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, CAGR (2021-2028)
FIGURE 25 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, LIFELINE CURVE
FIGURE 26 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2021
FIGURE 27 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2019-2028 (USD Million)
FIGURE 28 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, CAGR (2021-2028)
FIGURE 29 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, LIFELINE CURVE
FIGURE 30 Europe CAR-T cell therapy treatment market: BY brand, 2020
FIGURE 31 Europe CAR-T cell therapy treatment market: BY brand, 2020-2028 (USD Million)
FIGURE 32 Europe CAR-T cell therapy treatment market: BY brand, CAGR (2020-2028)
FIGURE 33 Europe CAR-T cell therapy treatment market: BY brand, LIFELINE CURVE
FIGURE 34 Europe CAR-T cell therapy treatment market: BY therapeutic application, 2020
FIGURE 35 Europe CAR-T cell therapy treatment market: BY therapeutic application, 2020-2028 (USD Million)
FIGURE 36 Europe CAR-T cell therapy treatment market: BY therapeutic application, CAGR (2020-2028)
FIGURE 37 Europe CAR-T cell therapy treatment market: BY therapeutic application, LIFELINE CURVE
FIGURE 38 Europe CAR-T cell therapy treatment market: BY END USER, 2020
FIGURE 39 Europe CAR-T cell therapy treatment market: BY END USER, 2020-2028 (USD Million)
FIGURE 40 Europe CAR-T cell therapy treatment market: BY END USER, CAGR (2020-2028)
FIGURE 41 Europe CAR-T cell therapy treatment market: BY END USER, LIFELINE CURVE
FIGURE 42 Europe CAR-T cell therapy treatment market: BY distribution channel, 2020
FIGURE 43 Europe CAR-T cell therapy treatment market: BY distribution channel, 2020-2028 (USD Million)
FIGURE 44 Europe CAR-T cell therapy treatment market: BY distribution channel, CAGR (2020-2028)
FIGURE 45 Europe CAR-T cell therapy treatment market: BY distribution channel, LIFELINE CURVE
FIGURE 46 Europe CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)
FIGURE 47 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)
FIGURE 48 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)
FIGURE 49 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)
FIGURE 50 Europe CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)
FIGURE 51 EUROPE CAR-T Cell Therapy Treatment Market: company share 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
